Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma

被引:22
作者
Kao, CH
Hsieh, JF
Ho, YJ
Ding, HJ
机构
[1] Taichung Vet Gen Hosp, Dept Nucl Med, Taichung, Taiwan
[2] Taipei Municipal Jen Ai Hosp, Dept Radiol, Taipei, Taiwan
[3] Kaohsiung Med Coll, Dept Nucl Med, Kaohsiung, Taiwan
[4] Kaohsiung Med Coll, Sch Technol Med Sci, Kaohsiung, Taiwan
关键词
cytokeratin fragment 19 (CYFRA 21-1); carcinoembryonic antigen; lung adenocarcinoma;
D O I
10.1007/PL00007651
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Fifty patients with adenocarcinoma of the lung were enrolled in this study, including 20 patients with recurrence and 30 patients without recurrence 1 year after surgery. Serial serum levels of cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen (CEA) were measured before the operation and 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months after surgery for the early detection of recurrence. The results revealed that the mean serum values of either CYFRA 21-1 or CEA were significantly higher until 9 and 12 months after surgery in the 20 patients with recurrent adenocarcinoma compared with the 30 patients without recurrent adenocarcinoma. We conclude that CYFRA 21-1 is not a better marker than CEA for early prediction of adenocarcinoma. We conclude that CYFRA 21-1 is not a better marker than CEA for early prediction of adenocarcinoma recurrence in lung.
引用
收藏
页码:333 / 337
页数:5
相关论文
共 19 条
[1]
Bodenmueller Heinz, 1994, International Journal of Biological Markers, V9, P75
[2]
BODENMULLER H, 1992, TUMOR ASS ANTIGENS O, P37
[3]
BROERS JLV, 1988, CANCER RES, V48, P3221
[4]
BROERS JLV, 1987, CANCER RES, V47, P3225
[5]
SQUAMOUS-CELL CARCINOMA ANTIGEN AS AN ADJUNCT TUMOR-MARKER IN PRIMARY-CARCINOMA OF THE LUNG [J].
CHEAH, PL ;
LIAM, CK ;
YAP, SF ;
LOOI, LM .
JOURNAL OF CLINICAL PATHOLOGY, 1994, 47 (06) :535-537
[6]
CONCANNON JP, 1978, CANCER, V42, P1477, DOI 10.1002/1097-0142(197809)42:3+<1477::AID-CNCR2820420818>3.0.CO
[7]
2-E
[8]
DEBUS E, 1984, AM J PATHOL, V114, P121
[9]
HABETS JMW, 1989, ANTICANCER RES, V9, P65
[10]
HOEFLIGER M, 1994, SCHWEIZ MED WSCHR, V124, P1966